Literature DB >> 11438837

Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.

Y Chen1, P Lenert, R Weeratna, M McCluskie, T Wu, H L Davis, A M Krieg.   

Abstract

The unmethylated CpG motifs within E. coli DNA (EC) cause immune stimulation. In contrast, mammalian DNA such as calf thymus (CT) DNA had been thought to be immunologically inert. In this article, we demonstrate that CT DNA unexpectedly specifically inhibits the immune activation by EC but not that by endotoxin. This inhibitory effect was mediated in the signaling pathway activated by EC since CT DNA markedly inhibited the CpG-induced nuclear translocation of the transcription factors, NF-kappaB and AP-1. In addition, CT DNA significantly inhibited the synergistic immune activation by EC and endotoxin. The mechanism of the inhibition by CT DNA probably did not involve the inhibition of the cellular uptake of EC. Using a CpG-depleted plasmid, we demonstrated that CpG methylation played an important role in the inhibition by CT DNA. Compared with unmethylated plasmid DNA, CpG-methylated DNA inhibited the immune activation by EC to the same extent as did CT DNA. Importantly, the inhibitory effect of CT DNA was also observed in vivo. Our results suggest that methylated DNA may be applied to alleviate the unwanted immune stimulation and inflammation in systemic inflammatory response syndrome and in gene therapy with plasmid DNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438837     DOI: 10.1038/sj.gt.3301482

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  17 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Design of modular non-viral gene therapy vectors.

Authors:  Laura De Laporte; Jennifer Cruz Rea; Lonnie D Shea
Journal:  Biomaterials       Date:  2005-10-21       Impact factor: 12.479

Review 3.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

4.  Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Authors:  Petar Lenert; Adam Goeken; Barry S Handwerger; Robert F Ashman
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

Review 5.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

7.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 8.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

9.  Treg-inducing capacity of genomic DNA of Bifidobacterium longum subsp. infantis.

Authors:  Dongmei Li; Jie Cheng; Ziang Zhu; Marta Catalfamo; David Goerlitz; Oliver J Lawless; Luke Tallon; Lisa Sadzewicz; Richard Calderone; Joseph A Bellanti
Journal:  Allergy Asthma Proc       Date:  2020-09-01       Impact factor: 2.587

Review 10.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.